Compare UMH & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UMH | RLAY |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | UMH | RLAY |
|---|---|---|
| Price | $15.88 | $8.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $17.75 | $16.00 |
| AVG Volume (30 Days) | 641.3K | ★ 2.1M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $256,272,000.00 | $8,355,000.00 |
| Revenue This Year | $10.80 | $20.47 |
| Revenue Next Year | $8.34 | N/A |
| P/E Ratio | $203.10 | ★ N/A |
| Revenue Growth | ★ 8.96 | N/A |
| 52 Week Low | $13.95 | $1.78 |
| 52 Week High | $19.75 | $8.70 |
| Indicator | UMH | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 64.38 | 65.59 |
| Support Level | $14.96 | $7.42 |
| Resistance Level | $15.51 | $8.70 |
| Average True Range (ATR) | 0.25 | 0.43 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 85.60 | 68.37 |
UMH Properties Inc together with its subsidiaries is a real estate investment trust. It is engaged in the business of ownership and operation of manufactured home communities - leasing manufactured homesites to residents . The Company also leases manufactured homes to residents and, through its wholly-owned taxable REIT subsidiary, UMH Sales and Finance, Inc. sells and finances the sale of manufactured homes to residents and prospective residents of its communities and for placement on customers' privately-owned land. The company also owns the land, utility connections, streets, lighting, driveways, common area amenities, and other capital improvements. It earns income from lease agreements for their sites and homes, where the company is the lessor.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).